PROGRAM :

13:30-14:00 REGISTRATION

Chair: Dr. Alan Palmer
Chief Scientific Officer, MS Therapeutics Ltd

14:00 Prof. Alan Thompson
Director, UCL Institute of Neurology
Welcome / Neuroscience Research at UCL

14:15 Dr. Jonathan H. Dempsey
Technology Specialist, Invitrogen
Addressing the needs of Neuroscience Research

14:30 Prof. Tony Schapira
Head, Department of Clinical Neurosciences
UCL Institute of Neurology
Current and future prospects of drugs and trials for
Parkinson’s disease

14:50 Prof. John Hardy , FRS
Chair of Molecular Biology of Neurological Disease
UCL Institute of Neurology
Genetics of Parkinsonisms

15:10 Prof. David Selwood
Founder, ProAxon and Canbex Therapeutics
Symptom relief and preventing neurodegeneration: two
essential components of new MS therapy

15:30 COFFEE BREAK

Chair: Dr. Michael O’Neill
Managing Director, Eolas Biosciences Ltd

15:55 Dr. Paolo Muraro
Division of Neurosciences & Mental Health
Imperial College London
Therapeutic potential of bone marrow-derived stem cells in multiple sclerosis

16:15 Prof. Simon Lovestone
Director, NIHR Biomedical Research Centre for Mental Health
Plasma biomarkers for Alzheimer’s disease:
the AddNeuroMed Experience

16:35 Dr. Jonathan Schott
Dementia Research Centre, UCL Institute of Neurology
Imaging in Alzheimer’s Disease: from early diagnosis to clinical trials

16:55 Dr. Mohammad S. Alavijeh
Managing Director, Pharmidex
Addressing the needs of CNS drug discovery

17:15 Dr. Tony Jones
Director, London Biotechnology Network
Closing Remarks

17:20-19:00 Distribute BIOGUIDE booklets/ Drinks & Canapes / Networking

Date: Monday 06 July 2009 – Monday 06 July 2009

Location: UCL Institute of Neurology